Menu
Back to Journals » Therapeutics and Clinical Risk Management » Volume 9
An update of teriflunomide for treatment of multiple sclerosis
Authors Oh J, O'Connor PW
Received 1 November 2012
Accepted for publication 11 December 2012
Published 26 April 2013 Volume 2013:9 Pages 177—190
DOI https://doi.org/10.2147/TCRM.S30947
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Jiwon Oh,1,2 Paul W O’Connor2
1Department of Neurology, Johns Hopkins University, Baltimore, MD, USA; 2Division of Neurology, St Michael’s Hospital, Toronto, ON, Canada
Abstract: There are a number of oral agents emerging as potential disease-modifying agents in multiple sclerosis (MS). Among these investigational agents, teriflunomide has shown promise in large, multicenter, phase III clinical trials with respect to safety and efficacy in relapsing MS patients, and is the latest disease-modifying agent approved for use in MS patients in the United States. This review will summarize teriflunomide's historical development, clinical pharmacology, studies in animals, clinical trials, and safety data, and will end with a discussion of the role of teriflunomide in MS in the context of existing treatment options.
Keywords: teriflunomide, multiple sclerosis, clinical trials, review
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.